Zhejiang Cancer Hospital: Breast Neoplasms trials

The registry lists 42 Breast Neoplasms studies with Zhejiang Cancer Hospital as lead sponsor. 15 are open to participants now and 1 have results posted.

Phase 1 1Phase 2 17Phase 3 2Phase 4 1No phase 22(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Research on AI Models for Predicting Breast Cancer Treatment Effectiveness to Guide Her-2 Targeted ADC TherapyNot yet recruitingNCT07689929
• A Study on the Efficacy and Safety of Switching Between Two Targeted Strategies, HP+Chemotherapy and HPy+Chemotherapy, After Treatment Progression in HER-2 Positive Advanced or Metastatic Breast CancerRecruitingNCT07455188
• A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine TherapyRecruitingNCT07330544Phase 2
• A Real-world Study on the Compliance of OFS-assisted Endocrine Therapy for Hormone Receptor-positive(HR+) Premenopausal Breast CancerNot yet recruitingNCT07180914
• Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast CancerRecruitingNCT07014410Phase 2
• To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.RecruitingNCT06784921
• Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical StudyRecruitingNCT06538896Phase 2
• Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical TrialNot yet recruitingNCT06308939Phase 2
• Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast CancerNot yet recruitingNCT06254066Phase 2
• The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.Not yet recruitingNCT06140576Phase 1/2
• Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABCRecruitingNCT05856383
• Effect of Zoledronic Acid Treatment on Bone-related Events in Breast Cancer Patients With Bone Metastases: a Prospective, Multicenter, Real-world StudyNot yet recruitingNCT05480189
• Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination DeficiencyNot yet recruitingNCT05461690Phase 2
• The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast CancerRecruitingNCT05075512Phase 2
• RecurIndex Predicts Risk of Recurrence in Early-stage Luminal Breast CancerNot yet recruitingNCT04972448
• CK19 Combined With Contrast-enhanced Ultrasound: a Prediction System on Axillary Lymph Node Metastasis in Breast CancerCompletedNCT02992067Results posted
• Real World Study of Bone Metastases in Patients with Advanced Breast CancerCompletedNCT06873997
• Dynamic Contrast-enhanced MRI Combined With IVIM-DWI for Early Prediction of Chemosensitivity in Liver MBCStatus unknownNCT05550090
• Transversus Thoracic Muscle Plane Combined With Pectoral Nerves Block for Breast Cancer SurgeryCompletedNCT05448638Not applicable
• Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBCStatus unknownNCT05131841Phase 4
• PTC Guiding Neoadjuvant Treatment in Breast CancerCompletedNCT05103293Phase 2
• Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations StudyCompletedNCT05054166
• A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast CancerStatus unknownNCT05030519
• Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese PatientsStatus unknownNCT04858997Phase 2
• Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast CancerStatus unknownNCT04665986Phase 3
• Correlation Between Molecular Typing and Neoadjuvant Chemotherapy in Breast Cancer Patients Based on Mammaprint/Blueprint TestStatus unknownNCT04264468
• Preoperative Systemic Therapy vs Upfront Surgery in HER2 Positive Early Breast CancerCompletedNCT04249440
• Endostar in Combination With Chemotherapy in HER-2 Negative Advanced Breast CancerStatus unknownNCT03907098Phase 2
• Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBCStatus unknownNCT03876587Phase 2
• Capecitabine in the Treatment of Breast Cancer With Low-hormone Receptor Expression After Neoadjuvant ChemotherapyStatus unknownNCT03821454Not applicable
• The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast CancerStatus unknownNCT03756090Not applicable
• Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast CancerStatus unknownNCT03756064Not applicable
• Abraxane Combined With Xeloda as Neo-Adjuvant Chemotherapy in Early Breast CancerStatus unknownNCT03647514Not applicable
• The Efficacy and Safety of Abraxane Combined With Epirubicin as Neoadjuvant Chemotherapy in Breast CancerStatus unknownNCT03647280Not applicable
• Recurrence Score-guiding Chemotherapy in Non-pCR HR Positive HER2 Negative Breast Cancer After Neoadjuvant TherapyStatus unknownNCT03638648Phase 2
• Remifemin Preventing the Climacteric Symptoms in Breast CancerCompletedNCT03339882Phase 2
• A Prospective Validation Cohort Study of a Prediction System on nSLN Metastasis in Early Breast CancerStatus unknownNCT03280134Not applicable
• Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast CancerStatus unknownNCT03204734Phase 2
• Docetaxel 2-weeks Regimen in the Treatment of HER2 Negative Metastatic Breast CancerStatus unknownNCT03147963Phase 2
• Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast CancerStatus unknownNCT02769104Phase 3
• Thalidomide Plus Chemotherapy Versus Chemotherapy Alone for Advanced Breast CancerStatus unknownNCT02649101Phase 2
• A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep)Status unknownNCT02597868Not applicable